Page 2 - Read Online

Special Issue Introduction:

The gut microbiota consists of a complex community of microorganisms, including bacteria, fungi,
viruses, and archaea. Advances in microbiome research and metagenomics have greatly enhanced our
understanding of the gut microbiota, with recent studies revealing that gut microbes are closely linked to
host health, especially in relation to metabolic diseases.

Metabolic diseases, such as obesity, type 2 diabetes, non-alcoholic fatty liver disease, and cardiovascular
disease, arise from metabolic disorders and persist over time or may even be lifelong. Studies have shown
that metabolic diseases are related to genetics, dietary habits, lifestyle choices, environmental influences,
and other factors; importantly, gut microbiota has been identified as one of the significant contributors.

Understanding the role of gut microbiota in the development of metabolic diseases, as well as how they
can be leveraged to prevent these diseases, has significant implications for treatment strategies. Long-term
drug treatments, for instance, may alter the diversity and abundance of microbes, potentially impacting
host health. New microbial sequencing and experimental techniques are now enabling deeper insights into
gut microbiota function and the mechanisms through which microbial metabolites contribute to metabolic
diseases.

This Special Issue of Microbiome Research Reports will present recent findings on this topic. We aim
to explore the roles of gut microbiota in the development of metabolic diseases, and to identify specific
microorganisms that could be targeted for the prevention and treatment of these conditions through
microbial interventions.

Topics in this Special Issue will include, but are not limited to:
1. Changes in gut microbiota and their roles in the development of metabolic diseases;
2. Screening and identification of gut microbiota for the prevention and treatment of metabolic diseases,
and insights into related regulatory mechanisms;
3. The impact of gut microbiota during drug treatment for metabolic diseases;
4. The influence of lifestyle factors (dietary habits, lifestyle choices, environmental exposures) on gut
microbes and metabolic diseases.